NAMS
NewAmsterdam Pharma Company N.V.
There isn't enough reported data to score NAMS yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
NAMS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
NAMS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
NAMS PE Valuation
NAMS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
NAMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect NAMS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
NAMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.68 | +$0.33 |
| Q2 2026 | -$2.15 | -$0.57 |
| Q1 2026 | -$1.78 | +$0.06 |
| Q4 2025 | -$1.72 | +$0.84 |
| Q3 2025 | -$2.01 | +$0.16 |
| Q2 2025 | -$1.58 | +$0.97 |
| Q1 2025 | -$1.84 | +$0.73 |
| Q4 2024 | -$2.56 | -$0.58 |
NAMS is still losing money, but far less than before: $1.68 per share over the past year, against $3.66 at its worst in late 2023.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over NAMS on earnings quality, reporting a profit while its opponent remains loss making.
NAMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.2M | +5407% |
| Q2 2026 | $3.7M | -81% |
| Q1 2026 | $3M | +2.1% |
| Q4 2025 | $32K | -100% |
| Q3 2025 | $348K | -99% |
| Q2 2025 | $19.1M | +740% |
| Q1 2025 | $3M | +113% |
| Q4 2024 | $12.8M | +1491% |
NAMS's revenue is recovering but still below its 2022 peak: $19M last quarter, up 5407% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -231% | +15615 points |
| Q2 2026 | -1753% | -1567 points |
| Q1 2026 | -1922% | +393 points |
| Q4 2025 | -206188% | -205849 points |
| Q3 2025 | -15846% | -15760 points |
| Q2 2025 | -186% | +2121 points |
| Q1 2025 | -2314% | +1646 points |
| Q4 2024 | -338% | +6022 points |
NAMS's operating margin was −231% last quarter, up 15615 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over NAMS on profitability, with a higher operating margin.
NAMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40M | -$7.1M |
| Q2 2026 | -$39.3M | -$1.5M |
| Q1 2026 | -$30.6M | +$5.8M |
| Q4 2025 | -$41M | -$3.5M |
| Q3 2025 | -$32.8M | -$20.2M |
| Q2 2025 | -$37.8M | +$16.4M |
| Q1 2025 | -$36.5M | +$18.5M |
| Q4 2024 | -$37.5M | -$4.4M |
NAMS has burned cash in almost every quarter: −$151M over the past year, against −$145M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over NAMS on cash generation, producing positive trailing cash flow while its opponent burns cash.
NAMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +766K shares |
| 1 year | +4.3% | +5.1M shares |
| 3 years | +51% | +41.7M shares |
| 5 years | +44% | +38M shares |
NAMS has 124M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over NAMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
NAMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -55.9x | Net Cash |
| Q2 2022 | -2.7x | Net Cash |
| Q1 2022 | -16.5x | Net Cash |
NAMS has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
NAMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 10.1 | Oversold |
NAMS's weekly RSI is 34 (neutral) and its Stochastic is 10 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
NAMS PE vs Healthcare Sector
| Metric | NAMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NAMS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
NAMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.7 | 3.7% below |
| 20 week MA | $25.2 | 21% below |
| 50 week MA | $30.0 | 33% below |
| 100 week MA | $27.3 | 27% below |
| 200 week MA | $21.4 | 6.6% below |
NAMS is in a downtrend: it's below all five of its weekly moving averages, and 6.6% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over NAMS on trend strength, trading above more of its moving averages.
NAMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.6 | $9.74 | -8.5% |
| 2022 | $9.74 | $11.3 | +16% |
| 2023 | $11.3 | $11.2 | -1.2% |
| 2024 | $11.2 | $25.9 | +132% |
| 2025 | $25.9 | $35.3 | +36% |
| 2026 YTD | $35.3 | $20.0 | -43% |
NAMS is down 43% so far in 2026, after finishing higher in three of the previous five years.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over NAMS on returns for 2026, with the stronger performance.